Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
|Videos|December 7, 2017
Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.
Advertisement
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma (RCC).
KEYNOTE-564 is an ongoing trial that is randomizing patients to pembrolizumab (Keytruda) or placebo, with a primary endpoint of disease-free survival.
This trial is enrolling high-risk patients with RCC, says Zhang, but it will also enroll patients with metastatic disease and have had metastasectomies—which is a unique feature of KEYNOTE-564.
Advertisement
Related to this article
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5